Advertisement

Psychopharmacology

, Volume 123, Issue 1, pp 98–102 | Cite as

Potentiation of the effects of raclopride on sucrose consumption by the 5-HT2 antagonist ritanserin

  • A. M. J. Montgomery
  • A. Suri
Original Investigation

Abstract

We examined the effects on sucrose consumption of a dopamine (DA) D2/D3 antagonist (raclopride, 0–0.3 mg/kg), a serotonin 5-HT2/2c antagonist (ritanserin, 0–0.4 mg/kg), and raclopride (0.15 mg/kg) combined with ritanserin (0–0.4 mg/kg). Three different concentrations of sucrose solution (0.7%, 7.0% and 34%) were tested. The concentration-intake function in drug-free rats was an inverted-U, with 7.0% sucrose supporting the highest intake. Raclopride (0.3 mg/kg) inhibited intake of 7.0% sucrose, but its effect on 0.7% sucrose fell short of significance (P<0.06) and intake of 34% sucrose was unchanged. Ritanserin did not affect sucrose intake when given on its own, but synergized with a previously ineffective dose of raclopride (0.15 mg/kg) so as to cause a significant inhibition of 7.0% sucrose intake and increase in 34% sucrose intake. These data indicate that 5-HT2 antagonism potentiated the behavioural effects of raclopride and we speculate that this interaction might contribute to the efficacy of atypical neuroleptic drugs.

Key words

Sucrose Raclopride 5-HT2 antagonism Rat 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Balsara JJ, Jadhav JH, Chandorkar AG (1979) Effects of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62:67–69Google Scholar
  2. Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1990) 5HT-2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13:500–506Google Scholar
  3. Davis JM, Janicak PG (1994) Efficacy and safety of the new antipsychotics. Lancet 343:476–477Google Scholar
  4. Gerlach J (1991) New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 17:289–309Google Scholar
  5. Kane J (1992) Atypical neuroleptics in the treatment of schizophrenia. In: Lindenmayer J-P, Kay SR (eds) New biological vistas on schizophrenia. Bruner/Mazel, New YorkGoogle Scholar
  6. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796Google Scholar
  7. Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5-HT2 receptors. Psychopharmacology 112:S40-S54Google Scholar
  8. Livingston MG (1994) Risperidone. Lancet 343:457–460Google Scholar
  9. Meert TF (1993) Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. Alcohol Alcohol 28:157–170Google Scholar
  10. Meert TF, Awouters F, Niemegeers CJE, Schellekens KHL, Janssen PAJ (1991) Ritanserin reduces abuse of alcohol, cocaine and fentanyl in rats. Pharmacopsychiatry 24:159–163Google Scholar
  11. Meltzer HY (1992) The importance of serotonin dopamine interactions in the action of clozapine. Br J Psychiatry 160:22–29Google Scholar
  12. Meltzer HY, Bastani B, Ramirez L, Matsubara S (1989) Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatr Neurol Sci 238:332–339Google Scholar
  13. Montgomery AMJ, Willner P (1988) Fenfluramine disrupts the behavioural satiety sequence in rats. Psychopharmacology 94:397–401Google Scholar
  14. Panocka I, Pompei P, Massi M (1993) Suppression of alcohol preference in rats induced by risperidone, a serotonin 5-HT2 and dopamine D2 receptor antagonist. Brain Res Bull 31:595–599Google Scholar
  15. Phillips G, Willner P, Muscat R (1991a) Reward-dependent suppression or facilitation of consummatory behaviour by raclopride. Psychopharmacology 105:355–360Google Scholar
  16. Phillips G, Willner P, Muscat R (1991b) Anatomical substrates for neuroleptic-induced reward attenuation and neurolepticinduced response decrement. Behav Pharmacol 2:129–141Google Scholar
  17. Seeman (1980) Brain dopamine receptors. Pharmacol Rev 32:229–313Google Scholar
  18. Waldmeier PC, Delini-Stula AA (1979) Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55:363–373Google Scholar
  19. Wiesel F-A, Nordstrom A-L, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114:31–38Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • A. M. J. Montgomery
    • 1
  • A. Suri
    • 1
  1. 1.Psychology DepartmentLondon Guildhall UniversityLondonUK

Personalised recommendations